Literature DB >> 25610750

Recent advances and new opportunities for targeting human dendritic cells in situ.

Madhav V Dhodapkar1, Kavita M Dhodapkar1.   

Abstract

Targeting antigens directly to dendritic cells (DCs) in situ has emerged as a promising strategy to potentiate immunity. A recent clinical trial of antibody-mediated targeting of tumor antigen NY-ESO1 to the DC receptor DEC-205 demonstrated an induction of strong cellular and humoral responses. Recent studies with DC-targeting via nanoparticles suggest that combinatorial targeting of multiple human DC subsets may further improve the efficacy of DC targeting.

Entities:  

Keywords:  DC, dendritic cells; NP, nanoparticles; TLR, toll-like receptors; dendritic cells; immunotherapy; vaccine

Year:  2014        PMID： 25610750      PMCID： PMC4292727          DOI： 10.4161/21624011.2014.954832

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

Review 1.  Decisions about dendritic cells: past, present, and future.

Authors:  Ralph M Steinman
Journal:  Annu Rev Immunol       Date:  2011-11-17       Impact factor: 28.527

Review 2.  Division of labor, plasticity, and crosstalk between dendritic cell subsets.

Authors:  Bali Pulendran; Hua Tang; Timothy L Denning
Journal:  Curr Opin Immunol       Date:  2007-12-21       Impact factor: 7.486

3.  Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity.

Authors:  Takemasa Tsuji; Junko Matsuzaki; Marcus P Kelly; Venky Ramakrishna; Laura Vitale; Li-Zhen He; Tibor Keler; Kunle Odunsi; Lloyd J Old; Gerd Ritter; Sacha Gnjatic
Journal:  J Immunol       Date:  2010-12-13       Impact factor: 5.422

4.  Improved cellular and humoral immune responses in vivo following targeting of HIV Gag to dendritic cells within human anti-human DEC205 monoclonal antibody.

Authors:  Cheolho Cheong; Jae-Hoon Choi; Laura Vitale; Li-Zhen He; Christine Trumpfheller; Leonia Bozzacco; Yoonkyung Do; Godwin Nchinda; Sung Ho Park; Durga Bhavani Dandamudi; Elina Shrestha; Maggi Pack; Han-Woong Lee; Tibor Keler; Ralph M Steinman; Chae Gyu Park
Journal:  Blood       Date:  2010-07-28       Impact factor: 22.113

5.  Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk.

Authors:  Kartik Sehgal; Ragy Ragheb; Tarek M Fahmy; Madhav V Dhodapkar; Kavita M Dhodapkar
Journal:  J Immunol       Date:  2014-07-30       Impact factor: 5.422

Review 6.  Dendritic-cell-based therapeutic cancer vaccines.

Authors:  Karolina Palucka; Jacques Banchereau
Journal:  Immunity       Date:  2013-07-25       Impact factor: 31.745

7.  Induction of antigen-specific immunity with a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205.

Authors:  Madhav V Dhodapkar; Mario Sznol; Biwei Zhao; Ding Wang; Richard D Carvajal; Mary L Keohan; Ellen Chuang; Rachel E Sanborn; Jose Lutzky; John Powderly; Harriet Kluger; Sheela Tejwani; Jennifer Green; Venky Ramakrishna; Andrea Crocker; Laura Vitale; Michael Yellin; Thomas Davis; Tibor Keler
Journal:  Sci Transl Med       Date:  2014-04-16       Impact factor: 17.956

Review 8.  Dendritic cell-based nanovaccines for cancer immunotherapy.

Authors:  Leonie E Paulis; Subhra Mandal; Martin Kreutz; Carl G Figdor
Journal:  Curr Opin Immunol       Date:  2013-04-06       Impact factor: 7.486

9.  Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo.

Authors:  D Hawiger; K Inaba; Y Dorsett; M Guo; K Mahnke; M Rivera; J V Ravetch; R M Steinman; M C Nussenzweig
Journal:  J Exp Med       Date:  2001-09-17       Impact factor: 14.307

10.  SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer.

Authors:  Kavita M Dhodapkar; Scott N Gettinger; Rituparna Das; Henry Zebroski; Madhav V Dhodapkar
Journal:  Oncoimmunology       Date:  2013-06-10       Impact factor: 8.110
  10 in total
  4 in total

Review 1.  Trial watch: Dendritic cell-based anticancer therapy.

Authors:  Norma Bloy; Jonathan Pol; Fernando Aranda; Alexander Eggermont; Isabelle Cremer; Wolf Hervé Fridman; Jitka Fučíková; Jérôme Galon; Eric Tartour; Radek Spisek; Madhav V Dhodapkar; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2014-12-21       Impact factor: 8.110

2.  Intranasal Vaccination with Mannosylated Chitosan Formulated DNA Vaccine Enables Robust IgA and Cellular Response Induction in the Lungs of Mice and Improves Protection against Pulmonary Mycobacterial Challenge.

Authors:  Manli Wu; Haoxin Zhao; Min Li; Yan Yue; Sidong Xiong; Wei Xu
Journal:  Front Cell Infect Microbiol       Date:  2017-10-16       Impact factor: 5.293

3.  Vaccination with poly(IC:LC) and peptide-pulsed autologous dendritic cells in patients with pancreatic cancer.

Authors:  Shikhar Mehrotra; Carolyn D Britten; Steve Chin; Elizabeth Garrett-Mayer; Colleen A Cloud; Mingli Li; Gina Scurti; Mohamed L Salem; Michelle H Nelson; Melanie B Thomas; Chrystal M Paulos; Andres M Salazar; Michael I Nishimura; Mark P Rubinstein; Zihai Li; David J Cole
Journal:  J Hematol Oncol       Date:  2017-04-07       Impact factor: 17.388

4.  Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.

Authors:  Sanne Duinkerken; Sophie K Horrevorts; Hakan Kalay; Martino Ambrosini; Lisa Rutte; Tanja D de Gruijl; Juan J Garcia-Vallejo; Yvette van Kooyk
Journal:  Theranostics       Date:  2019-08-12       Impact factor: 11.556
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.